Greg Pyszczymuka - 31 Mar 2025 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Reporting relationship: Chief Commercial Officer
Issuer ticker: AYTU
Reported as of: 31 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2025, 16:34:24 UTC
Prior SEC filing: 24 Feb 2025
Next SEC filing: 22 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Ryan Selhorn as attorney-in-fact for Greg Pyszczymuka

Key filing fact

Greg Pyszczymuka filed Form 4 for AYTU BIOPHARMA, INC (AYTU) on 31 Mar 2025.

Key facts

This page summarizes Greg Pyszczymuka's Form 4 filing for AYTU BIOPHARMA, INC (AYTU).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Mar 2025, 16:34.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AYTU transaction

Common Shares

Options Exercise

Transaction value
Shares: +209
Change %: +0.89%
Price
Shares after: 23,602
Date: 31 Mar 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AYTU transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -209
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 31 Mar 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 209
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.